Table 2.

Rituximab treatment protocols

FDA-APPROVED PROTOCOLS30

375mg/m2 IV infusion once weekly for 4 to 8 consecutive weeks (NHL)

Two 1,000mg IV infusions separated by two weeks (RA)

OFF-LABEL PROTOCOLS IN THE LITERATURE

1–3mL (10mg/mL) intralesional injections three times weekly for 1 or 2 cycles at a four-week interval (PCBCL)50,53

375mg/m2 IV infusion once weekly for 2 to 4 consecutive weeks (PV)8,39

100 or 375mg/m2 IV infusion once weekly for four consecutive weeks (DM)69

375mg/m2 IV once weekly for eight consecutive weeks with one cycle of 2mg/kg IVIG at Weeks 4 and 8, followed by monthly rituximab and IVIG cycles for four consecutive months (PV)42

FDA = US Food and Drug Administration; IV = intravenous; NHL = non-Hodgkin“s lymphoma; RA = rheumatoid arthritis; PCBCL = primary cutaneous B-cell lymphoma; PV = pemphigus vulgaris; DM = dermatomyositis; IVIG = intravenous immunoglobulin